BUZZ-Sichuan Kelun-Biotech jumps on approval for investigational new drug

Reuters06-18

** Shares of Sichuan Kelun-Biotech Biopharmaceutical

jump 4.8% to HK$180.5, their highest since June 11

** Stock on course for second session of gain; second biggest pct gainer in Hong Kong's healthcare index

** Co says it has received clinical trial notice from the National Medical Products Administration (NMPA) approving the investigational new drug application for its drug SKB518 for injection to treat advanced solid tumors

** In accordance with the notice, co plans to organise and implement a clinical trial of SKB518 for injection

** Hong Kong's healthcare index falls 1.7%, Hang Seng Composite Index slips 0.1% and Hang Seng Index eases 0.2%

** Stock up 73.5% YTD

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444173855?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-18 13:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444173855","market":"hk","top_or_hot":-1,"title":"BUZZ-Sichuan Kelun-Biotech jumps on approval for investigational new drug","media":"Reuters","content":"<html><body><p>** Shares of Sichuan Kelun-Biotech Biopharmaceutical</p><p>  jump 4.8% to HK$180.5, their highest since June 11</p><p>   ** Stock on course for second session of gain; second biggest pct gainer in Hong Kong's healthcare index   </p><p>   ** Co says it has received clinical trial notice from the National Medical Products Administration (NMPA) approving the investigational new drug application for its drug SKB518 for injection to treat advanced solid tumors </p><p>   ** In accordance with the notice, co plans to organise and implement a clinical trial of SKB518 for injection</p><p>   ** Hong Kong's healthcare index falls 1.7%, Hang Seng Composite Index    slips 0.1% and Hang Seng Index    eases 0.2%</p><p>   ** Stock up 73.5% YTD  </p><p> (Reporting by Donny Kwok)</p><p>((donny.kwok@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Sichuan Kelun-Biotech jumps on approval for investigational new drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Sichuan Kelun-Biotech jumps on approval for investigational new drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-18 13:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>** Shares of Sichuan Kelun-Biotech Biopharmaceutical  jump 4.8% to HK$180.5, their highest since June 11   ** Stock on course for second session of gain; second biggest pct gainer in Hong Kong's ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2444173855","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444173855","pubTimestamp":1718688588,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Shares of Sichuan Kelun-Biotech Biopharmaceutical  jump 4.8% to HK$180.5, their highest since June 11   ** Stock on course for second session of gain; second biggest pct gainer in Hong Kong's healthcare index      ** Co says it has received clinical trial notice from the National Medical Products Administration  approving the investigational new drug application for its drug SKB518 for injection to treat advanced solid tumors    ** In accordance with the notice, co plans to organise and implement a clinical trial of SKB518 for injection   ** Hong Kong's healthcare index falls 1.7%, Hang Seng Composite Index    slips 0.1% and Hang Seng Index    eases 0.2%   ** Stock up 73.5% YTD   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","06990":"科伦博泰生物-B"},"translate_title":"嗡嗡声-四川科伦生物因新药获批而跃升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":0.9},"content_text":"** Shares of Sichuan Kelun-Biotech Biopharmaceutical  jump 4.8% to HK$180.5, their highest since June 11   ** Stock on course for second session of gain; second biggest pct gainer in Hong Kong's healthcare index      ** Co says it has received clinical trial notice from the National Medical Products Administration (NMPA) approving the investigational new drug application for its drug SKB518 for injection to treat advanced solid tumors    ** In accordance with the notice, co plans to organise and implement a clinical trial of SKB518 for injection   ** Hong Kong's healthcare index falls 1.7%, Hang Seng Composite Index    slips 0.1% and Hang Seng Index    eases 0.2%   ** Stock up 73.5% YTD   (Reporting by Donny Kwok)((donny.kwok@thomsonreuters.com))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444173855"}